Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997831 | 0.89 | SLC6A4 (0.65) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL16269692 | 0.87 | EPHX2 (0.53) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL5994452 | 0.87 | EPHX2 (0.48) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL5995931 | 0.86 | SLC6A4 (0.51) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL5994154 | 0.84 | SLC6A4 (0.62) | SLC6A4SLC6A2EPHX2 | |
| SCHEMBL16268663 | 0.83 | EPHX2 (0.50) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL16269490 | 0.83 | JAK2 (0.52) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL6186753 | 0.81 | EPHX2 (0.48) | SLC6A4SLC6A2EPHX2MEN1KMT2A | |
| SCHEMBL5993362 | 0.80 | ALDH1A1 (0.48) | SLC6A4SLC6A2MEN1KMT2ASLC6A3 | |
| SCHEMBL5995606 | 0.80 | SLC6A2 (0.51) | SLC6A4SLC6A2EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | ELI LILLY AND COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | SLC6A2, SLC18A2, SLC6A3 | SLC6A4 4/4885SLC6A2 1/4885EPHX2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.